New York, United States
Nephrogen, founded in 2022, is a burgeoning player in the biotechnology and health care industries, with a mission conveyed succinctly through its slogan: "Curative gene therapies for kidney diseases." This United States-based company is pioneering efforts to address unmet medical needs, namely focusing initially on polycystic kidney disease (PKD), which affects around 600,000 Americans and currently lacks effective treatments or cures.
While still in its early stages, Nephrogen has already attracted notable attention. In its last reported funding round on 01 September 2020, the startup received Non Equity Assistance investment from prominent startup incubators Y Combinator and StartX. The involvement of such esteemed institutions underscores investor confidence in Nephrogen's innovative efforts and potential market impact. With a strategic focus on health and wellness, the company stands poised to advance significant breakthroughs in gene therapy solutions for kidney diseases.
